Immutep (IMMP) Shares Outstanding (2011 - 2025)
Immutep's (IMMP) quarterly Shares Outstanding (Entity) came in at $1.5 billion in Q2 2025, up 21.21% YoY from $1.2 billion in Q2 2024, and up 21.21% on a QoQ basis from $1.2 billion in Q2 2024.
Immutep (IMMP) Shares Outstanding (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 12 years of Shares Outstanding (Entity) data on file, last reported at $1.5 billion in Q2 2025.
- Quarterly Shares Outstanding (Entity) rose 21.21% year-over-year to $1.5 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.5 billion (up 21.21% YoY) and the FY2025 annual result came in at $1.5 billion, up 21.21% from the prior year.
- Shares Outstanding (Entity) rose to $1.5 billion in Q2 2025, from $1.2 billion in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $1.5 billion in Q2 2025 to a low of $594.9 million in Q2 2021.
- A 5-year average of $998.6 million and a median of $892.4 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) surged 48.37% — and 2023, when it gained 5.12%.
- Tracing IMMP's Shares Outstanding (Entity) over 5 years: stood at $594.9 million in 2021, then surged by 42.7% to $849.0 million in 2022, then rose by 5.12% to $892.4 million in 2023, then soared by 34.59% to $1.2 billion in 2024, then rose by 21.21% to $1.5 billion in 2025.
- The last three Shares Outstanding (Entity) figures came in at $1.5 billion (Q2 2025), $1.2 billion (Q2 2024), and $892.4 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | 145.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.46 Bn |
| Dec 31, 2024 | 1.20 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Dec 31, 2023 | 892.40 Mn |
| Jun 30, 2023 | 892.40 Mn |
| Dec 31, 2022 | 848.97 Mn |
| Jun 30, 2022 | 848.97 Mn |
| Dec 31, 2021 | 594.93 Mn |
| Jun 30, 2021 | 594.93 Mn |
| Dec 31, 2020 | 400.98 Mn |
| Jun 30, 2020 | 400.98 Mn |
| Dec 31, 2019 | 322.56 Mn |
| Jun 30, 2019 | 322.56 Mn |
| Dec 31, 2018 | 260.83 Mn |
| Jun 30, 2018 | 260.83 Mn |
| Jun 30, 2017 | 228.44 Mn |
| Mar 31, 2017 | 207.49 Mn |
| Dec 31, 2016 | 222.85 Mn |
| Jun 30, 2016 | 222.85 Mn |